Angioedème héréditaire de type III : Questions médicales fréquentes
Nom anglais: Hereditary Angioedema Type III
Descriptor UI:D056828
Tree Number:C20.543.480.904.066.500.500
Termes MeSH sélectionnés :
Angiotensin II Type 2 Receptor Blockers
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Angioedème héréditaire de type III : Questions médicales les plus fréquentes",
"headline": "Angioedème héréditaire de type III : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Angioedème héréditaire de type III : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-20",
"dateModified": "2025-02-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Angioedème héréditaire de type III"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Angioedème",
"url": "https://questionsmedicales.fr/mesh/D000799",
"about": {
"@type": "MedicalCondition",
"name": "Angioedème",
"code": {
"@type": "MedicalCode",
"code": "D000799",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.543.480.904.066"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Angioedème héréditaire de type III",
"alternateName": "Hereditary Angioedema Type III",
"code": {
"@type": "MedicalCode",
"code": "D056828",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Timothy Craig",
"url": "https://questionsmedicales.fr/author/Timothy%20Craig",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam (L.M.F., D.M.C.); the Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla (M.A.R.), Ionis Pharmaceuticals, Carlsbad (L.B., V.J.A., K.B.N., A.R., B.F.B., C.N., A.R.M., E.S.), and the Division of Allergy, Immunology, and Rheumatology, University of California, Los Angeles, Los Angeles (R.T.) - all in California; the Department of Internal Medicine, Division of Immunology-Allergy Section and the Bernstein Clinical Research Center, University of Cincinnati College of Medicine, Cincinnati (J.A.B.); the Midwest Immunology Clinic, Plymouth, MN (J.R.); the Department of Medicine and Pediatrics, Penn State Health Allergy, Asthma, and Immunology, Hershey, PA (T.C.); Asthma and Allergy Research Associates, Dallas (W.R.L.); and Medical Research of Arizona, Scottsdale (M.E.M.)."
}
},
{
"@type": "Person",
"name": "Danny M Cohn",
"url": "https://questionsmedicales.fr/author/Danny%20M%20Cohn",
"affiliation": {
"@type": "Organization",
"name": "Amsterdam UMC, University of Amsterdam, Department of Vascular Medicine, Amsterdam, the Netherlands."
}
},
{
"@type": "Person",
"name": "Marc A Riedl",
"url": "https://questionsmedicales.fr/author/Marc%20A%20Riedl",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam (L.M.F., D.M.C.); the Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla (M.A.R.), Ionis Pharmaceuticals, Carlsbad (L.B., V.J.A., K.B.N., A.R., B.F.B., C.N., A.R.M., E.S.), and the Division of Allergy, Immunology, and Rheumatology, University of California, Los Angeles, Los Angeles (R.T.) - all in California; the Department of Internal Medicine, Division of Immunology-Allergy Section and the Bernstein Clinical Research Center, University of Cincinnati College of Medicine, Cincinnati (J.A.B.); the Midwest Immunology Clinic, Plymouth, MN (J.R.); the Department of Medicine and Pediatrics, Penn State Health Allergy, Asthma, and Immunology, Hershey, PA (T.C.); Asthma and Allergy Research Associates, Dallas (W.R.L.); and Medical Research of Arizona, Scottsdale (M.E.M.)."
}
},
{
"@type": "Person",
"name": "Konrad Bork",
"url": "https://questionsmedicales.fr/author/Konrad%20Bork",
"affiliation": {
"@type": "Organization",
"name": "Hautklinik, Universitätsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland."
}
},
{
"@type": "Person",
"name": "Yuxiang Zhi",
"url": "https://questionsmedicales.fr/author/Yuxiang%20Zhi",
"affiliation": {
"@type": "Organization",
"name": "Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Neuroprotective effect of angiotensin II receptor blockers on the risk of incident Alzheimer's disease: A nationwide population-based cohort study.",
"datePublished": "2023-03-06",
"url": "https://questionsmedicales.fr/article/36949774",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fnagi.2023.1137197"
}
},
{
"@type": "ScholarlyArticle",
"name": "Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease.",
"datePublished": "2024-04-29",
"url": "https://questionsmedicales.fr/article/38682786",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD006257.pub2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria.",
"datePublished": "2022-10-07",
"url": "https://questionsmedicales.fr/article/36210196",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.mayocp.2022.07.010"
}
},
{
"@type": "ScholarlyArticle",
"name": "Combined vaccines against angiotensin II receptor type 1 and alpha 1D-adrenergic receptor for hypertension.",
"datePublished": "2024-03-11",
"url": "https://questionsmedicales.fr/article/38690916",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/HJH.0000000000003710"
}
},
{
"@type": "ScholarlyArticle",
"name": "Kidney Outcomes Following Angiotensin Receptor-Neprilysin Inhibitor vs Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy for Thrombotic Microangiopathy.",
"datePublished": "2024-09-03",
"url": "https://questionsmedicales.fr/article/39264627",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamanetworkopen.2024.32862"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système immunitaire",
"item": "https://questionsmedicales.fr/mesh/D007154"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hypersensibilité",
"item": "https://questionsmedicales.fr/mesh/D006967"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hypersensibilité immédiate",
"item": "https://questionsmedicales.fr/mesh/D006969"
},
{
"@type": "ListItem",
"position": 5,
"name": "Urticaire",
"item": "https://questionsmedicales.fr/mesh/D014581"
},
{
"@type": "ListItem",
"position": 6,
"name": "Angioedème",
"item": "https://questionsmedicales.fr/mesh/D000799"
},
{
"@type": "ListItem",
"position": 7,
"name": "Angioedème héréditaire de type III",
"item": "https://questionsmedicales.fr/mesh/D056828"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Angioedème héréditaire de type III - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Angioedème héréditaire de type III",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Angioedème héréditaire de type III",
"description": "Comment est diagnostiqué l'angioedème héréditaire de type III ?\nQuels tests sont utilisés pour confirmer le diagnostic ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?\nQuel rôle joue l'historique familial dans le diagnostic ?\nLes tests cutanés sont-ils utiles pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D056828?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=8#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Angioedème héréditaire de type III",
"description": "Quels sont les symptômes typiques de l'angioedème héréditaire de type III ?\nLes épisodes d'angioédème sont-ils douloureux ?\nÀ quelle fréquence surviennent les épisodes ?\nLes symptômes peuvent-ils apparaître sans déclencheur ?\nLes symptômes affectent-ils la respiration ?",
"url": "https://questionsmedicales.fr/mesh/D056828?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=8#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Angioedème héréditaire de type III",
"description": "Comment prévenir les épisodes d'angioédème ?\nLes patients doivent-ils porter un bracelet médical ?\nL'éducation des patients est-elle importante ?\nLes vaccinations sont-elles recommandées ?\nLes patients doivent-ils éviter le stress ?",
"url": "https://questionsmedicales.fr/mesh/D056828?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=8#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Angioedème héréditaire de type III",
"description": "Quels traitements sont disponibles pour l'angioedème héréditaire de type III ?\nLes patients doivent-ils éviter certains aliments ?\nLes traitements préventifs sont-ils efficaces ?\nLes corticostéroïdes sont-ils utilisés en urgence ?\nY a-t-il des traitements expérimentaux disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D056828?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=8#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Angioedème héréditaire de type III",
"description": "Quelles complications peuvent survenir avec l'angioédème héréditaire ?\nL'angioédème peut-il entraîner des hospitalisations ?\nLes complications sont-elles fréquentes ?\nLes complications peuvent-elles être évitées ?\nLes complications affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D056828?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=8#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Angioedème héréditaire de type III",
"description": "Quels sont les facteurs de risque de l'angioédème héréditaire ?\nL'âge influence-t-il le risque d'angioédème ?\nLe sexe joue-t-il un rôle dans le risque ?\nLes antécédents médicaux augmentent-ils le risque ?\nLes facteurs environnementaux influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D056828?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=8#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment est diagnostiqué l'angioedème héréditaire de type III ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'anamnèse, les antécédents familiaux et des tests génétiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de dosage des protéines C1 inhibiteur et des tests génétiques sont effectués."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent être similaires à ceux d'autres formes d'angioedème."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'historique familial dans le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un historique familial positif est crucial pour suspecter un angioedème héréditaire."
}
},
{
"@type": "Question",
"name": "Les tests cutanés sont-ils utiles pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les tests cutanés ne sont pas efficaces pour diagnostiquer ce type d'angioédème."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes typiques de l'angioedème héréditaire de type III ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des gonflements soudains, souvent au visage, aux mains et aux pieds."
}
},
{
"@type": "Question",
"name": "Les épisodes d'angioédème sont-ils douloureux ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les épisodes peuvent être inconfortables, mais ils ne sont généralement pas douloureux."
}
},
{
"@type": "Question",
"name": "À quelle fréquence surviennent les épisodes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La fréquence varie, certains patients ayant des épisodes fréquents, d'autres moins."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils apparaître sans déclencheur ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent survenir sans cause identifiable, ce qui complique le traitement."
}
},
{
"@type": "Question",
"name": "Les symptômes affectent-ils la respiration ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans certains cas, le gonflement peut affecter la respiration, nécessitant une attention médicale."
}
},
{
"@type": "Question",
"name": "Comment prévenir les épisodes d'angioédème ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les déclencheurs connus et suivre un traitement préventif peut aider."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils porter un bracelet médical ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un bracelet médical peut informer les secours en cas d'urgence liée à l'angioédème."
}
},
{
"@type": "Question",
"name": "L'éducation des patients est-elle importante ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur la maladie et ses déclencheurs est essentielle pour la gestion."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles recommandées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations sont recommandées, mais doivent être discutées avec un médecin."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils éviter le stress ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut être un déclencheur, donc des techniques de gestion du stress sont utiles."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour l'angioedème héréditaire de type III ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments antihistaminiques et des corticostéroïdes."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils éviter certains aliments ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas d'aliments spécifiques à éviter, mais certains peuvent déclencher des épisodes."
}
},
{
"@type": "Question",
"name": "Les traitements préventifs sont-ils efficaces ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements préventifs peuvent réduire la fréquence et la gravité des épisodes."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils utilisés en urgence ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent être administrés en cas d'épisodes sévères."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements expérimentaux, comme les inhibiteurs de bradykinine, sont en cours d'étude."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'angioédème héréditaire ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des obstructions respiratoires et des infections secondaires."
}
},
{
"@type": "Question",
"name": "L'angioédème peut-il entraîner des hospitalisations ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des épisodes graves peuvent nécessiter une hospitalisation pour traitement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications ne sont pas fréquentes mais peuvent survenir dans des cas sévères."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par une gestion appropriée de la maladie."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de l'angioédème héréditaire ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque incluent des antécédents familiaux et des mutations génétiques."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'angioédème ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le risque peut augmenter avec l'âge, mais il est souvent présent dès l'enfance."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le sexe n'influence pas significativement le risque d'angioédème héréditaire."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux augmentent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents médicaux de maladies auto-immunes peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains facteurs environnementaux peuvent déclencher des épisodes, mais ne sont pas des risques directs."
}
}
]
}
]
}
Recent studies on renin-angiotensin system (RAS) inhibitors have reported a reduced risk of Alzheimer's disease (AD). Nevertheless, the effect of RAS inhibitor type and blood-brain barrier (BBB) perme...
To assess the effects of RAS inhibitors on the risk of AD based on the type and BBB permeability and investigate the cumulative duration-response relationship....
This was a population-based retrospective cohort study using the Korean Health Insurance Review and Assessment database records from 2008 to 2019. The data of patients diagnosed with ischemic heart di...
Among the 57,420 matched individuals, 7,303 developed AD within the follow-up period. While the use of angiotensin-converting enzyme inhibitors (ACEIs) was not significantly associated with AD risk, t...
Long-term use of BBB-crossing ARBs significantly reduced the risk of AD development. The finding may provide valuable insight into disease-modifying drug options for preventing AD in patients with car...
Guidelines suggest that adults with diabetes and kidney disease receive treatment with angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). This is an update of a Co...
We compared the efficacy and safety of ACEi and ARB therapy (either as monotherapy or in combination) on cardiovascular and kidney outcomes in adults with diabetes and kidney disease....
We searched the Cochrane Kidney and Transplants Register of Studies to 17 March 2024 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register...
We included studies evaluating ACEi or ARB alone or in combination, compared to each other, placebo or no treatment in people with diabetes and kidney disease....
Two authors independently assessed the risk of bias and extracted data. Summary estimates of effect were obtained using a random-effects model, and results were expressed as risk ratios (RR) and their...
One hundred and nine studies (28,341 randomised participants) were eligible for inclusion. Overall, the risk of bias was high. Compared to placebo or no treatment, ACEi may make little or no differenc...
ACEi or ARB may make little or no difference to all-cause and cardiovascular death compared to placebo or no treatment in people with diabetes and kidney disease but may prevent kidney failure. ARB ma...
For persons with proteinuria, angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs) are treatment mainstays for reducing kidney disease progression. Guidelines f...
Compared with monotherapy, combination therapy with multiple antihypertensive drugs has demonstrated superior efficacy in the management of hypertension. The aim of this study was to explore the effic...
Our team has developed ATRQβ-001 and ADRQβ-004 vaccines targeting Ang II type 1 receptor (AT1R) and α1D-adrenergic receptor (α1D-AR), respectively. In NG-nitroarginine methyl ester (l-NAME) + abilitie...
Both ATRQβ-001 and ADRQβ-004 vaccines induced robust antibody production, resulting in persistent high antibody titers in rats. Notably, the combined administration of both vaccines significantly decr...
Preliminary findings from this investigation suggest that co-administration of the novel ATRQβ-001 and ADRQβ-004 vaccines holds potential as a groundbreaking therapeutic strategy for managing hyperten...
Thrombotic microangiopathy (TMA) on kidney biopsy is a pattern of endothelial injury commonly seen in malignant hypertension (mHTN), but treatment strategies are not well established....
To evaluate the kidney outcomes of angiotensin receptor-neprilysin inhibitor (ARNI), specifically sacubitril/valsartan, vs angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocke...
This single-center cohort study enrolled consecutive patients in China diagnosed with mHTN-associated TMA through kidney biopsy from January 2008 to June 2023. Follow-up was conducted until the conclu...
Treatment with sacubitril/valsartan or ACEI/ARBs during hospitalization and after discharge....
The primary outcome was a composite of kidney recovery: a 50% decrease in serum creatinine level, decrease in serum creatinine levels to the reference range, or kidney survival free from dialysis for ...
Among the 217 patients (mean [SD] age, 35.9 [8.8] years; 188 men [86.6%]) included in the study, 66 (30.4%) received sacubitril/valsartan and 151 (69.6%) received ACEI/ARBs at baseline. Sacubitril/val...
In this cohort study, sacubitril/valsartan treatment was associated with a potential kidney function benefit in patients with mHTN-associated TMA compared with ACEI/ARB treatment. The findings suggest...
Renin-angiotensin-aldosterone system (RAAS) is hypothesized to be in the center of COVID pathophysiology as the angiotensin converting enzyme 2 (ACE2) represents the main entrance of the virus, thus t...
A total of 40 healthy controls and 60 Egyptian patients suffering from chronic cardiovascular diseases were enrolled in this study. Patients were divided into 40 patients treated with ACEIs and 20 pat...
Assessment of serum ACE2 level in different groups showed a significant difference between ACEIs and healthy groups and ACEIs and ARBs group, while there was no difference between ARBs and healthy. Mu...
ACE2 levels varied between ACEIs and ARBs. It tends to be lower in ACEIs group and there is a strong positive association between ACE2 level and the female sex. This needs to be considered in Future s...
Retrospectively registered ClinicalTrials.gov ID: NCT05418361 (June 2022)....
Increased titers of autoantibodies targeting the G-protein-coupled receptors angiotensin II type 1 receptor (AT1R) and endotelin-1 type A receptor (ETAR) are associated with severe coronavirus disease...
Antibodies against AT1R, ETAR, and antinuclear antibodies (ANAs) were measured in n=40 prospectively enrolled COVID-19 patients and n=207 COVID-19 patients included in a biobank. Clinical and laborato...
Significantly increased AT1R and ETAR antibody titers were found in COVID-19 patients compared to controls, while titers were equal between favorable and unfavorable COVID-19 disease course groups. On...
In patients hospitalized for COVID-19, antibodies against AT1R and ETAR are increased compared to controls and patients with ARDS due to other causes than COVID-19. The baseline antibody titers do not...
Advancing age could influence renin angiotensin system components, especially angiotensin type 1 receptor (AT1R). This study examined the effect of AT1R antagonist, losartan, on age-related difference...
Forty-eight anesthetized male and female rats (8-12 and 24-28 weeks age ranges) were subjected to catheterize. Then, the responses of mean arterial pressure (MAP), renal perfusion pressure (RPP), rena...
There were not significant differences in the basal values of MAP, RPP, RBF, and RVR in males. However, it was observed significant difference in RVR in females (...
Losartan could maintain RBF changes in response to angiotensin II in both 8-12- and 24-28-week females. Losartan enhanced the RBF response to angiotensin II in 8-12-week males, but not in 24-28-week m...
Acute myocardial infarction (MI) is one of the leading global healthcare emergencies, contributing to over three million global deaths. The purpose of this study is to investigate further the efficacy...
Arterial hypertension is the main preventable cause of premature mortality worldwide. Across Latin America, hypertension has an estimated prevalence of 25.5-52.5%, although many hypertensive patients ...